Success in medtech innovation requires more than groundbreaking technology. During a panel at LSI USA ‘24, Ivanny Franklin of NAMSA emphasized the pivotal role of clinical and regulatory strategies in shaping investment decisions and driving long-term outcomes. Joined by distinguished panelists—Auriel August of Santé Ventures, Edwin Lindsay of Compliance Solutions Life Sciences, Nir Goldenberg of Mayo Clinic Ventures, and Adam Saltman of NAMSA—Franklin explored how regulatory rigor and clinical diligence intersect with investment value.